Prosecution Insights
Last updated: April 19, 2026
Application No. 18/518,099

EYELASH COATING COMPOSITIONS FOR FALSE EYELASHES

Final Rejection §112
Filed
Nov 22, 2023
Examiner
AL-AWADI, DANAH J
Art Unit
1615
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
L'Oréal
OA Round
4 (Final)
53%
Grant Probability
Moderate
5-6
OA Rounds
3y 3m
To Grant
68%
With Interview

Examiner Intelligence

Grants 53% of resolved cases
53%
Career Allow Rate
423 granted / 795 resolved
-6.8% vs TC avg
Moderate +14% lift
Without
With
+14.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
41 currently pending
Career history
836
Total Applications
across all art units

Statute-Specific Performance

§101
2.7%
-37.3% vs TC avg
§103
46.9%
+6.9% vs TC avg
§102
15.1%
-24.9% vs TC avg
§112
20.2%
-19.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 795 resolved cases

Office Action

§112
DETAILED ACTION RESPONSE TO AMENDMENT 1. Receipt of Applicants’ amendments and arguments/remarks filed 9/12/2025 are acknowledged. INFORMATION DISCLOSURE STATEMENT 2. No new Information Disclosure Statement has been submitted for review. WITHDRAWN REJECTIONS 3. Rejections not reiterated from previous Office Actions are hereby withdrawn. The following rejections are either reiterated or newly applied. They constitute the complete set presently being applied to the instant application. NEW REJECTIONS Claim Rejections- 35 USC § 112 d 4. The following is a quotation of 35 U.S.C. 112(d): (d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph: Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers. Claim 3 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends. Claim 3 recites “wherein the method consists of applying the eyelash coating composition of claim 1 to natural eyelashes, applying artificial eyelashes to the natural eyelashes upon which the composition has been applied and allowing the composition to dry such that the artificial eyelashes attach to the natural eyelashes” and this limitation has already been encompassed by claim 1. Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements. CONCLUSION 5. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. CORRESPONDENCE 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Danah Al-awadi whose telephone number is (571) 270-7668. The examiner can normally be reached on 9:00 am- 6:00 pm; M-F (EST). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert A. Wax can be reached on (571) 272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll- free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272 1000. /DANAH AL-AWADI/Primary Examiner, Art Unit 1615
Read full office action

Prosecution Timeline

Nov 22, 2023
Application Filed
Jun 29, 2024
Non-Final Rejection — §112
Oct 07, 2024
Response Filed
Jan 24, 2025
Final Rejection — §112
May 29, 2025
Request for Continued Examination
Jun 05, 2025
Response after Non-Final Action
Jun 14, 2025
Non-Final Rejection — §112
Sep 12, 2025
Response Filed
Jan 24, 2026
Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599565
STABLE BENZIMIDAZOLE FORMULATION
2y 5m to grant Granted Apr 14, 2026
Patent 12589071
SUCKABLE AND/OR MELT-IN-MOUTH TABLET BASED ON HYALURONIC ACID AND CHONDROITIN SULPHATE AND SALTS THEREOF
2y 5m to grant Granted Mar 31, 2026
Patent 12582597
WAX OF NATURAL ORIGIN FOR COSMETIC PRODUCTS
2y 5m to grant Granted Mar 24, 2026
Patent 12582692
Methods And Kits For Reducing Microplastics Levels And/Or Reducing Or Minimizing Microplastics Accumulation Rates In Subjects
2y 5m to grant Granted Mar 24, 2026
Patent 12570641
SOLID FORMS OF A CDK4 INHIBITOR
2y 5m to grant Granted Mar 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

5-6
Expected OA Rounds
53%
Grant Probability
68%
With Interview (+14.3%)
3y 3m
Median Time to Grant
High
PTA Risk
Based on 795 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month